Salmonellosis future or investigational therapies
|
Salmonellosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Salmonellosis future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Salmonellosis future or investigational therapies |
|
Salmonellosis future or investigational therapies in the news |
|
Risk calculators and risk factors for Salmonellosis future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: João André Alves Silva, M.D. [2] Jolanta Marszalek, M.D. [3]
Overview
Future studies are required to better understand the association between the different manifestations of the disease, and the respective bacterial genotypes. Additionally it is necessary to create humanized mouse models that will allow us understand the pathophysiology of the disease, and to test new drugs and vaccines. Current drugs undergoing investigation include: new antibiotics, electrolyte absorption enhancers; blockers of inflammatory and secretory toxins; and promoters of the intestinal repair.[1][2]
Future or Investigational Therapies
The different genotypes of salmonella have been associated with different manifestations of the disease, yet, this connection is not fully understood. Future studies are required to explain the potential genetic basis for the development of invasive non-typhoidal salmonella, and why certain non-typhoidal salmonella strains cause more severe disease than others.[1]
Research to create a new generation of humanized mouse models is also required. These models will allow to understand more of the pathogenesis of salmonella in human tissues, as well as to test the efficacy of new treatments and vaccines.[1]
Current therapeutic drugs being studied include:[2]
- New antibiotics
- Inflammatory and secretory toxin blockers
- Electrolyte absorption enhancers
- Promoters of intestinal repair
References
- ↑ 1.0 1.1 1.2 Gal-Mor O, Boyle EC, Grassl GA (2014). "Same species, different diseases: how and why typhoidal and non-typhoidal Salmonella enterica serovars differ". Front Microbiol. 5: 391. doi:10.3389/fmicb.2014.00391. PMID 25136336.
- ↑ 2.0 2.1 Guerrant RL, Van Gilder T, Steiner TS, Thielman NM, Slutsker L, Tauxe RV; et al. (2001). "Practice guidelines for the management of infectious diarrhea". Clin Infect Dis. 32 (3): 331–51. doi:10.1086/318514. PMID 11170940.